Combined RAF and MEK inhibition to treat activated non-V600 BRAF-altered advanced cancers Journal Article
| Authors: | Rustgi, N.; Maria, A.; Toumbacaris, N.; Zhao, H.; Kargus, K.; Bryant, M.; Waksmundzki, A.; Aricescu, I.; Lefkowitz, R. A.; Li, B. T.; Chou, J.; Capanu, M.; de Stanchina, E.; Misale, S.; Shia, J.; Yaeger, R. |
| Article Title: | Combined RAF and MEK inhibition to treat activated non-V600 BRAF-altered advanced cancers |
| Abstract: | Background: Cancers with non-V600 BRAF-activating alterations have no matched therapy. Preclinical data suggest that these tumors depend on ERK signaling; however, clinical response to MEK/ERK inhibitors has overall been low. We hypothesized that a narrow therapeutic index, driven by ERK inhibition in healthy (wild-type) tissues, limits the efficacy of these inhibitors. As these mutants signal as activated dimers, we further hypothesized that RAF inhibitors given concurrently would improve the therapeutic index by opposing ERK inhibition in normal tissues and not activate ERK in the already activated tumor. Materials and Methods: Using cell lines and patient-derived xenografts, we evaluated the effect of RAF inhibition, alone and in combination with MEK/ERK inhibitors. We then undertook a phase I/II clinical trial of a higher dose of the MEK inhibitor binimetinib combined with the RAF inhibitor encorafenib in patients with advanced cancer with activating non-V600 BRAF alterations. Results: RAF inhibition led to modest inhibition of signaling and growth in activated non-V600 BRAF preclinical models and allowed higher dose of MEK/ERK inhibitors in vivo for more profound tumor regression. Fifteen patients received binimetinib 60 mg twice daily plus encorafenib 450 mg daily (6 gastrointestinal primaries, 6 genitourinary primaries, 3 melanoma, and 2 lung cancer; 7 BRAF mutations and 8 BRAF fusions). Treatment was well tolerated without dose-limiting toxicities. One patient had a confirmed partial response, 8 had stable disease, and 6 had radiographic or clinical progression as best response. On-treatment biopsies revealed incomplete ERK pathway inhibition. Conclusion: Combined RAF and MEK inhibition does not sufficiently inhibit activated non-V600 BRAF-mutant tumors in patients. © 2024 Wiley-Blackwell. All rights reserved. |
| Keywords: | genetics; mutation; melanoma; protein kinase inhibitor; protein kinase inhibitors; sulfonamide; sulfonamides; b raf kinase; mitogen activated protein kinase kinase; mitogen-activated protein kinase kinases; braf; mek; proto-oncogene proteins b-raf; braf protein, human; translational research; humans; human; precision medicine; encorafenib |
| Journal Title: | The Oncologist |
| Volume: | 29 |
| Issue: | 1 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-01-01 |
| Start Page: | 15 |
| End Page: | 24 |
| Language: | English |
| DOI: | 10.1093/oncolo/oyad247 |
| PUBMED: | 37616543 |
| PROVIDER: | scopus |
| PMCID: | PMC10769795 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Rona Yaeger -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work